HRP20192085T1 - Metoda dijagnosticiranja fetalnog alkoholnog spektra poremećaja - Google Patents
Metoda dijagnosticiranja fetalnog alkoholnog spektra poremećaja Download PDFInfo
- Publication number
- HRP20192085T1 HRP20192085T1 HRP20192085TT HRP20192085T HRP20192085T1 HR P20192085 T1 HRP20192085 T1 HR P20192085T1 HR P20192085T T HRP20192085T T HR P20192085TT HR P20192085 T HRP20192085 T HR P20192085T HR P20192085 T1 HRP20192085 T1 HR P20192085T1
- Authority
- HR
- Croatia
- Prior art keywords
- amount
- pigf
- chips
- blot
- methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 25
- 208000026934 fetal alcohol spectrum disease Diseases 0.000 title claims 3
- 238000003745 diagnosis Methods 0.000 title claims 2
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 claims 14
- 102100035194 Placenta growth factor Human genes 0.000 claims 14
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 claims 13
- 201000007794 fetal alcohol syndrome Diseases 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 238000002965 ELISA Methods 0.000 claims 3
- 238000001262 western blot Methods 0.000 claims 3
- 239000012472 biological sample Substances 0.000 claims 2
- 238000011984 electrochemiluminescence immunoassay Methods 0.000 claims 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 claims 2
- 238000003364 immunohistochemistry Methods 0.000 claims 2
- 238000001114 immunoprecipitation Methods 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 238000003757 reverse transcription PCR Methods 0.000 claims 2
- 238000002798 spectrophotometry method Methods 0.000 claims 2
- 102100040685 14-3-3 protein zeta/delta Human genes 0.000 claims 1
- AQQSXKSWTNWXKR-UHFFFAOYSA-N 2-(2-phenylphenanthro[9,10-d]imidazol-3-yl)acetic acid Chemical compound C1(=CC=CC=C1)C1=NC2=C(N1CC(=O)O)C1=CC=CC=C1C=1C=CC=CC=12 AQQSXKSWTNWXKR-UHFFFAOYSA-N 0.000 claims 1
- 102100027314 Beta-2-microglobulin Human genes 0.000 claims 1
- 102100026031 Beta-glucuronidase Human genes 0.000 claims 1
- 102100021429 DNA-directed RNA polymerase II subunit RPB1 Human genes 0.000 claims 1
- 102100021699 Eukaryotic translation initiation factor 3 subunit B Human genes 0.000 claims 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims 1
- 101000964898 Homo sapiens 14-3-3 protein zeta/delta Proteins 0.000 claims 1
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 claims 1
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims 1
- 101000933465 Homo sapiens Beta-glucuronidase Proteins 0.000 claims 1
- 101001106401 Homo sapiens DNA-directed RNA polymerase II subunit RPB1 Proteins 0.000 claims 1
- 101000896557 Homo sapiens Eukaryotic translation initiation factor 3 subunit B Proteins 0.000 claims 1
- 101000988834 Homo sapiens Hypoxanthine-guanine phosphoribosyltransferase Proteins 0.000 claims 1
- 101000599449 Homo sapiens Importin-8 Proteins 0.000 claims 1
- 101001067833 Homo sapiens Peptidyl-prolyl cis-trans isomerase A Proteins 0.000 claims 1
- 101000579123 Homo sapiens Phosphoglycerate kinase 1 Proteins 0.000 claims 1
- 101000662049 Homo sapiens Polyubiquitin-C Proteins 0.000 claims 1
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 claims 1
- 102100037966 Importin-8 Human genes 0.000 claims 1
- 238000000636 Northern blotting Methods 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- KJWZYMMLVHIVSU-IYCNHOCDSA-N PGK1 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](CCCCCCC(O)=O)C(=O)CC1=O KJWZYMMLVHIVSU-IYCNHOCDSA-N 0.000 claims 1
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 claims 1
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 claims 1
- 102100037935 Polyubiquitin-C Human genes 0.000 claims 1
- 102100034391 Porphobilinogen deaminase Human genes 0.000 claims 1
- 101710189720 Porphobilinogen deaminase Proteins 0.000 claims 1
- 101710170827 Porphobilinogen deaminase, chloroplastic Proteins 0.000 claims 1
- 101710100896 Probable porphobilinogen deaminase Proteins 0.000 claims 1
- 101710156592 Putative TATA-binding protein pB263R Proteins 0.000 claims 1
- 238000003559 RNA-seq method Methods 0.000 claims 1
- 238000002105 Southern blotting Methods 0.000 claims 1
- 102100040296 TATA-box-binding protein Human genes 0.000 claims 1
- 101710145783 TATA-box-binding protein Proteins 0.000 claims 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims 1
- 238000002835 absorbance Methods 0.000 claims 1
- 238000004082 amperometric method Methods 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 238000004630 atomic force microscopy Methods 0.000 claims 1
- 238000000225 bioluminescence resonance energy transfer Methods 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 238000004624 confocal microscopy Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000002848 electrochemical method Methods 0.000 claims 1
- 238000001493 electron microscopy Methods 0.000 claims 1
- 238000000572 ellipsometry Methods 0.000 claims 1
- 230000005284 excitation Effects 0.000 claims 1
- 210000004700 fetal blood Anatomy 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 claims 1
- 238000004020 luminiscence type Methods 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 238000000386 microscopy Methods 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 210000002826 placenta Anatomy 0.000 claims 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 claims 1
- 235000002020 sage Nutrition 0.000 claims 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims 1
- 238000004611 spectroscopical analysis Methods 0.000 claims 1
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
- 238000002834 transmittance Methods 0.000 claims 1
- 238000004832 voltammetry Methods 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/515—Angiogenesic factors; Angiogenin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Peptides Or Proteins (AREA)
Claims (13)
1. Metoda in vitro dijagnosticiranja fetalnog alkoholnog spektra poremećaja (FASDs) kod subjekta koja obuhvaća sljedeće korake:
a) mjerenje količine placentalnog faktora rasta (PIGF) u biološkom uzorku od rečenog subjekta te;
b) uspoređivanje količine PIGF iz koraka a) s referencom, te
c) utvrđivanje FASD kod rečenog subjekta.
2. Metoda iz patentnog zahtjeva 1, naznačeno time da referenca jest mjerenje količine PIGF kod zdravog pojedinca.
3. Metoda iz bilo kojeg od patentnih zahtjeva 1 ili 2, naznačeno time da količina PIGF iz koraka a) niža od reference pokazuje da subjekt pati od FASD.
4. Metoda iz bilo kojeg od patentnih zahtjeva 1 do 3, naznačeno time da količina PIGF iz koraka a) niža od reference pokazuje cerebrovaskularni poremećaj kod subjekta.
5. Metoda iz bilo kojeg od patentnih zahtjeva 1 do 4, naznačeno time da je rečeni biološki uzorak dobiven iz placente, pogotovo iz krvi iz pupkovine.
6. Metoda iz bilo kojeg od patentnih zahtjeva 1 do 5, naznačeno time da je količina PIGF određena mjerenjem količine nukleinske kiseline od PIGF.
7. Metoda iz bilo kojeg od patentnih zahtjeva 1 do 6, naznačeno time da je količina PIGF mjerena metodom odabranom od Northern blot, Southern blot, PCR, RT-PCR, kvantitativni RT-PCR, SAGE i njihovih derivata, čipova nukleinske kiseline, posebno čipova cDNA, čipova oligonukleotida i čipova mRNA, čipova tkiva i RNA-Seq.
8. Metoda iz bilo kojeg od patentnih zahtjeva 1 do 7, naznačeno time da je količina PIGF određena mjerenjem količine polipeptida.
9. Metoda iz patentnog zahtjeva 8, naznačeno time da je količina PIGF mjerena metodom odabranom od imunohistologije, imunoprecipitacije, Western blot, dot blot, ELISA ili ELISPOT, ECLIA, čipova proteina, čipova antitijela, ili čipova tkiva povezanih s imunohistokemijom, tehnika FRET ili BRET, metoda mikroskopije ili histokemije, posebice uključujući metode konfokalne mikroskopije i elektronske mikroskopije, metoda temeljenih na upotrebi jedne ili više ekscitacijskih valnih duljina i pogodne optičke metode, kao što je elektrokemijska metoda (tehnike voltametrije i amperometrije), mikroskopija atomske sile, te metode radiofrekvencije, kao što je multipolarna rezonancijska spektroskopija, konfokalna i ne-konfokalna, detekcija fluorescencije, luminiscencije, kemiluminiscencije, apsorbancije, reflektancije, transmitancije, i birefrigencije ili indeksa loma (posebno rezonancijom površinskog plazmona, elipsometrijom ili rezonacijskom zrcalnom metodom), protočna citometrija, oslikavanje radioizotopom ili magentskom rezonancijom, analiza poliakrilamid gel elektroforezom (SDS-PAGE), HPLC-masena spektrofotometrija i tekućinska kromatografija-masena spektrofotometrija/masena spektrometrija (LC-MS/MS).
10. Metoda iz bilo kojeg od patentnih zahtjeva 8 ili 9, naznačeno time da je količina PIGF određena metodom odabranom od imunoprecipitacije, imunohistologije, Western blot, dot blot, ELISA ili ELISPOT, ECLIA, čipova proteina, čipova antitijela, ili čipova tkiva povezanih s imunohistokemijom.
11. Metoda iz bilo kojeg od patentnih zahtjeva 8 do 10, naznačeno time da je količina PIGF određena Western blotom ili ELISA.
12. Metoda iz bilo kojeg od patentnih zahtjeva 1 do 11, naznačeno time da je količina PIGF normalizirana relativno prema kontrolnom markeru.
13. Metoda iz patentnog zahtjeva 12, naznačeno time da je kontrolni marker gen odabran iz skupine koju čine B2M, TFRC, YWHAZ, RPLO, 18S, GUSB, UBC, TBP, GAPDH, PPIA, POLR2A, ACTB, PGK1, HPRT1, IPO8 te HMBS, ili polipeptid odabran od produkata rečenog gena.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1555727A FR3037657B1 (fr) | 2015-06-22 | 2015-06-22 | Methode de diagnostic des troubles causes par l'alcoolisation foetale |
| PCT/EP2016/064480 WO2016207253A1 (fr) | 2015-06-22 | 2016-06-22 | Methode de diagnostic des troubles causes par l'alcoolisation foetale |
| EP16736402.5A EP3311174B1 (fr) | 2015-06-22 | 2016-06-22 | Méthode de diagnostic des troubles causés par l'alcoolisation foetale |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20192085T1 true HRP20192085T1 (hr) | 2020-02-21 |
Family
ID=54329676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20192085TT HRP20192085T1 (hr) | 2015-06-22 | 2019-11-20 | Metoda dijagnosticiranja fetalnog alkoholnog spektra poremećaja |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10793908B2 (hr) |
| EP (1) | EP3311174B1 (hr) |
| JP (1) | JP6663936B2 (hr) |
| KR (1) | KR20180063036A (hr) |
| CN (1) | CN108450002A (hr) |
| AU (1) | AU2016282842A1 (hr) |
| BR (1) | BR112017027707A2 (hr) |
| CA (1) | CA2990304A1 (hr) |
| DK (1) | DK3311174T3 (hr) |
| ES (1) | ES2758424T3 (hr) |
| FR (1) | FR3037657B1 (hr) |
| HK (1) | HK1253894B (hr) |
| HR (1) | HRP20192085T1 (hr) |
| HU (1) | HUE047242T2 (hr) |
| PL (1) | PL3311174T3 (hr) |
| PT (1) | PT3311174T (hr) |
| WO (1) | WO2016207253A1 (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11041756B2 (en) | 2017-10-20 | 2021-06-22 | Charted Scientific Inc. | Method and apparatus of filtering light using a spectrometer enhanced with additional spectral filters with optical analysis of fluorescence and scattered light from particles suspended in a liquid medium using confocal and non confocal illumination and imaging |
| US10585028B2 (en) | 2017-10-20 | 2020-03-10 | Charted Scientific, Inc. | Method and apparatus for optical analysis |
| US20210102959A1 (en) * | 2018-04-10 | 2021-04-08 | Quanterix Corporation | Quantification of biomarkers present in physiological samples |
| FR3081707A1 (fr) * | 2018-05-30 | 2019-12-06 | Universite De Rouen Normandie | Traitement des troubles neurologiques causes par l'alcoolisation foetale |
| WO2020181263A1 (en) * | 2019-03-06 | 2020-09-10 | San Diego State University (SDSU) Foundation, dba San Diego State University Research Foundation | Methods and systems for continuous measurement and/or screening of anomalies for fetal alcohol spectrum disorder analysis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2534926T3 (es) * | 2002-07-19 | 2015-04-30 | Beth Israel Deaconess Medical Center | Métodos para tratar la preeclampsia |
| US20060037085A1 (en) * | 2004-08-13 | 2006-02-16 | Ying Peng | Animal model for fetal alcohol syndrome and methods of treatment |
| EP2125036A4 (en) * | 2006-12-08 | 2011-01-19 | Yin-Xiong Li | FORMATION AND REJUVENATION OF ORGANS AND REGENERATION OF ALCOHOL-DAMAGED ORGANS THROUGH STEM CELL NUTRIENTS |
| US8383352B2 (en) * | 2009-06-05 | 2013-02-26 | Northwestern University | Detection of maternal alcohol exposure |
| CN102895219A (zh) * | 2012-10-26 | 2013-01-30 | 中山大学孙逸仙纪念医院 | 虾青素在胎儿酒精相关性疾病中的应用 |
-
2015
- 2015-06-22 FR FR1555727A patent/FR3037657B1/fr not_active Expired - Fee Related
-
2016
- 2016-06-22 JP JP2017566398A patent/JP6663936B2/ja not_active Expired - Fee Related
- 2016-06-22 US US15/738,922 patent/US10793908B2/en active Active
- 2016-06-22 KR KR1020187001742A patent/KR20180063036A/ko not_active Application Discontinuation
- 2016-06-22 CN CN201680048286.8A patent/CN108450002A/zh active Pending
- 2016-06-22 BR BR112017027707-7A patent/BR112017027707A2/pt not_active IP Right Cessation
- 2016-06-22 AU AU2016282842A patent/AU2016282842A1/en not_active Abandoned
- 2016-06-22 CA CA2990304A patent/CA2990304A1/fr not_active Abandoned
- 2016-06-22 WO PCT/EP2016/064480 patent/WO2016207253A1/fr active Application Filing
- 2016-06-22 ES ES16736402T patent/ES2758424T3/es active Active
- 2016-06-22 PL PL16736402T patent/PL3311174T3/pl unknown
- 2016-06-22 HU HUE16736402A patent/HUE047242T2/hu unknown
- 2016-06-22 PT PT167364025T patent/PT3311174T/pt unknown
- 2016-06-22 EP EP16736402.5A patent/EP3311174B1/fr active Active
- 2016-06-22 DK DK16736402T patent/DK3311174T3/da active
-
2018
- 2018-10-11 HK HK18113035.0A patent/HK1253894B/zh unknown
-
2019
- 2019-11-20 HR HRP20192085TT patent/HRP20192085T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3311174A1 (fr) | 2018-04-25 |
| US10793908B2 (en) | 2020-10-06 |
| KR20180063036A (ko) | 2018-06-11 |
| HK1253894B (zh) | 2020-07-10 |
| US20180195124A1 (en) | 2018-07-12 |
| CA2990304A1 (fr) | 2016-12-29 |
| JP2018519819A (ja) | 2018-07-26 |
| JP6663936B2 (ja) | 2020-03-13 |
| ES2758424T3 (es) | 2020-05-05 |
| FR3037657A1 (fr) | 2016-12-23 |
| PL3311174T3 (pl) | 2020-03-31 |
| CN108450002A (zh) | 2018-08-24 |
| FR3037657B1 (fr) | 2017-06-23 |
| PT3311174T (pt) | 2019-11-22 |
| DK3311174T3 (da) | 2019-11-18 |
| HUE047242T2 (hu) | 2020-04-28 |
| AU2016282842A1 (en) | 2018-01-25 |
| WO2016207253A1 (fr) | 2016-12-29 |
| BR112017027707A2 (pt) | 2018-09-11 |
| EP3311174B1 (fr) | 2019-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192085T1 (hr) | Metoda dijagnosticiranja fetalnog alkoholnog spektra poremećaja | |
| Cai et al. | Phase separation of YAP reorganizes genome topology for long-term YAP target gene expression | |
| Ferby et al. | Mig6 is a negative regulator of EGF receptor–mediated skin morphogenesis and tumor formation | |
| JP2018519819A5 (hr) | ||
| ES2637411T3 (es) | Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95 | |
| Zhang et al. | Expression and functional characterization of ABCG2 in brain endothelial cells and vessels | |
| ES2695101T3 (es) | Análisis automatizado de células tumorales circulantes | |
| ES2705950T3 (es) | Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib | |
| CN103502470B (zh) | 嗅介蛋白-4蛋白（olfm4）在结肠直肠癌诊断中的用途 | |
| JP6612414B2 (ja) | Ｐｄ−ｌ１に対するｓｒｍアッセイ | |
| Purba et al. | Mapping the expression of epithelial hair follicle stem cell‐related transcription factors LHX 2 and SOX 9 in the human hair follicle | |
| Kotzsch et al. | Inverse association of rab31 and mucin-1 (CA15-3) antigen levels in estrogen receptor-positive (ER+) breast cancer tissues with clinicopathological parameters and patients’ prognosis | |
| Wang et al. | iSERS microscopy guided by wide field immunofluorescence: analysis of HER2 expression on normal and breast cancer FFPE tissue sections | |
| WO2014198995A1 (es) | Biomarcadores para el diagnóstico y respuesta al tratamiento en cáncer de páncreas | |
| Preusser et al. | Survivin expression in intracranial ependymomas and its correlation with tumor cell proliferation and patient outcome | |
| JP2009506303A (ja) | 癌の化学療法のための予測方法 | |
| Lu et al. | RETRACTED ARTICLE: Nrdp1 inhibits growth of colorectal cancer cells by nuclear retention of p27 | |
| CN105899673A (zh) | 作为子宫颈癌和存活期的生物标记物的角蛋白 | |
| Pennock et al. | Vascular endothelial cell growth factor A acts via platelet-derived growth factor receptor α to promote viability of cells enduring hypoxia | |
| JP2015525358A (ja) | 組織切片中の単一細胞におけるマーカー定量 | |
| EP3352859B1 (en) | Quantifying met protein for cancer treatment | |
| Zhang et al. | YT521 promotes metastases of endometrial cancer by differential splicing of vascular endothelial growth factor A | |
| US20190369106A1 (en) | Flow proteometric methods for digital quantification and binding analysis | |
| US20100303809A1 (en) | Methods for the detection and quantitation of pten | |
| Hemstreet III et al. | Intermediate endpoint biomarkers for chemoprevention |